Profile data is unavailable for this security.
About the company
JanOne Inc. is a clinical-stage pharmaceutical company. The Company is focused on identifying, acquiring, licensing, developing, partnering, and commercializing non-opioid and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. Its drug candidate, JAN101, is an oral pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities, such as those with vascular complications of diabetes or Peripheral Artery Disease (PAD) and treats pain. It operates in two segments: Biotechnology and Technology. Its biotechnology segment is focused on finding treatments for conditions that cause severe pain and to market drugs with non-addictive pain-relieving properties. Its recycling segment is an appliance recycling program, which offers recycling, replacement and additional services for utility energy efficiency programs and have established 20 Regional Processing Centers (RPCs) throughout the United States and Canada.
- Revenue in USD (TTM)0.00
- Net income in USD-17.10m
- Incorporated2018
- Employees5.00
- LocationJanone Inc325 E Warm Springs Rd Ste 102LAS VEGAS 89119-4240United StatesUSA
- Phone+1 (702) 997-5968
- Websitehttps://janone.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Brainstorm Cell Therapeutics Inc | 0.00 | -17.19m | 35.88m | 29.00 | -- | -- | -- | -- | -0.4079 | -0.4079 | 0.00 | -0.0803 | 0.00 | -- | -- | 0.00 | -271.62 | -117.19 | -- | -231.65 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 29.18 | -- | -45.34 | -- |
| Qsam Biosciences Inc | 0.00 | -5.16m | 36.19m | 4.00 | -- | 180.08 | -- | -- | -1.58 | -1.58 | 0.00 | 0.1863 | 0.00 | -- | -- | 0.00 | -424.48 | -944.58 | -- | -- | -- | -- | -- | -- | -- | -74.82 | 0.011 | -- | -- | -- | 15.04 | -- | -- | -- |
| Incannex Healthcare Inc | 163.39k | -13.70m | 36.19m | -- | -- | 1.92 | -- | 221.50 | -0.3806 | -0.3806 | 0.0003 | 1.19 | 0.0038 | -- | 0.0554 | -- | -31.42 | -54.94 | -32.90 | -59.47 | -- | -- | -8,386.19 | -1,033.07 | -- | -- | 0.00 | -- | 61.92 | 3.38 | -24.35 | -- | 54.12 | -- |
| Xilio Therapeutics Inc | 0.00 | -76.40m | 36.20m | 73.00 | -- | 0.7871 | -- | -- | -2.78 | -2.78 | 0.00 | 1.33 | 0.00 | -- | -- | 0.00 | -76.37 | -- | -93.74 | -- | -- | -- | -- | -- | -- | -131.89 | 0.0826 | -- | -- | -- | 13.40 | -- | -- | -- |
| Unicycive Therapeutics Inc | 675.00k | -31.41m | 37.19m | 14.00 | -- | -- | -- | 55.10 | -1.62 | -1.62 | 0.0276 | -0.1096 | 0.0794 | -- | -- | 48,214.29 | -359.15 | -218.20 | -- | -609.54 | -- | -- | -4,525.04 | -3,877.49 | -- | -- | -- | -- | -29.02 | -- | -73.95 | -- | -- | -- |
| Bright Green Corp | 0.00 | -13.13m | 37.60m | 5.00 | -- | 3.33 | -- | -- | -0.0732 | -0.0732 | 0.00 | 0.0594 | 0.00 | -- | -- | 0.00 | -64.24 | -- | -97.68 | -- | -- | -- | -- | -- | -- | -5,488.51 | 0.0181 | -- | -- | -- | 52.54 | -- | -- | -- |
| Estrella Immunopharma Inc | 0.00 | -2.16m | 37.71m | -- | -- | 3.60 | -- | -- | -1.90 | -1.90 | 0.00 | 0.2861 | 0.00 | -- | -- | -- | -5.92 | -- | -7.86 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -302.11 | -- | -- | -- |
| Ocuphire Pharma Inc | 19.05m | -9.99m | 38.21m | 14.00 | -- | 0.7399 | -- | 2.01 | -0.4735 | -0.4735 | 0.8727 | 2.08 | 0.3701 | -- | 5.30 | 1,360,643.00 | -19.40 | -58.31 | -20.77 | -65.94 | -- | -- | -52.42 | -137.92 | -- | -8.46 | 0.00 | -- | -52.20 | -- | -155.83 | -- | -- | -- |
| Natural Alternatives International, Inc. | 127.76m | -4.11m | 38.60m | 317.00 | -- | 0.4517 | 85.78 | 0.3021 | -0.705 | -0.705 | 21.87 | 14.03 | 0.8624 | 4.23 | 12.32 | 403,041.00 | -2.77 | 4.90 | -3.11 | 5.93 | 7.90 | 15.98 | -3.22 | 3.80 | 2.59 | -2.54 | 0.0988 | 0.00 | -9.91 | 3.06 | -76.46 | -20.74 | 27.08 | -- |
| Cara Therapeutics Inc | 20.97m | -118.51m | 38.65m | 55.00 | -- | 0.6748 | -- | 1.84 | -2.19 | -2.19 | 0.3872 | 1.05 | 0.1361 | 2.37 | 6.96 | 381,236.40 | -76.94 | -35.76 | -91.50 | -40.82 | 70.56 | -- | -565.21 | -162.10 | 4.43 | -- | 0.00 | -- | -49.92 | 9.26 | -38.65 | -- | 100.66 | -- |
| Janone Inc | 0.00 | -17.10m | 38.80m | 5.00 | -- | -- | -- | -- | -3.52 | -0.4564 | 0.00 | 2.26 | 0.00 | -- | -- | 0.00 | -52.40 | -23.12 | -96.58 | -62.22 | -- | 23.38 | -- | -30.14 | -- | -- | 0.0594 | -- | -- | -- | -313.15 | -- | -- | -- |
| Promis Neurosciences Inc | 0.00 | -13.21m | 38.87m | 6.00 | -- | 10.31 | -- | -- | -1.22 | -1.22 | 0.00 | 0.1987 | 0.00 | -- | -- | 0.00 | -128.63 | -144.28 | -552.70 | -262.23 | -- | -- | -- | -2,271,047.00 | -- | -- | 0.00 | -- | -- | -- | 26.85 | -- | -- | -- |
| ImmuCell Corp | 17.47m | -5.77m | 38.99m | 79.00 | -- | 1.56 | -- | 2.23 | -0.7454 | -0.7454 | 2.26 | 3.22 | 0.3941 | 1.96 | 8.86 | 221,160.40 | -13.03 | -5.16 | -14.19 | -5.53 | 22.15 | 40.04 | -33.05 | -12.64 | 0.8715 | -15.17 | 0.3238 | -- | -5.90 | 9.72 | -131.56 | -- | -1.39 | -- |
| Benson Hill Inc | 473.34m | -111.25m | 39.07m | 270.00 | -- | 0.4541 | -- | 0.0826 | -0.5914 | -0.6131 | 2.52 | 0.4129 | 1.22 | 10.27 | 14.81 | 1,753,096.00 | -28.68 | -- | -38.28 | -- | 4.99 | 3.18 | -23.50 | -40.73 | 0.9166 | -2.33 | 0.4509 | -- | 24.16 | 156.43 | -11.58 | -- | 63.78 | -- |
| Marker Therapeutics Inc | 3.31m | -14.05m | 39.40m | 8.00 | -- | 2.80 | -- | 11.90 | -1.59 | -0.933 | 0.3753 | 1.58 | 0.1285 | -- | 1.93 | 413,892.50 | -54.49 | -53.74 | -69.03 | -62.25 | -- | -- | -424.20 | -1,438.71 | -- | -- | 0.00 | -- | -5.76 | 74.27 | 28.97 | -- | -- | -- |
| SAB Biotherapeutics Inc | 2.24m | -42.19m | 40.22m | 57.00 | -- | 0.702 | -- | 17.96 | -7.18 | -7.18 | 0.4056 | 6.21 | 0.0332 | -- | 0.8059 | 39,280.53 | -62.58 | -- | -77.39 | -- | -- | -- | -1,884.50 | -- | -- | -- | 0.0743 | -- | -90.63 | -- | -125.14 | -- | -- | -- |
Data as of Apr 24 2024. Currency figures normalised to Janone Inc's reporting currency: US Dollar USD
6.27%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| LPL Financial LLCas of 31 Dec 2023 | 130.04k | 2.62% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 73.30k | 1.48% |
| Two Sigma Securities LLCas of 31 Dec 2023 | 29.83k | 0.60% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 15.98k | 0.32% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 15.70k | 0.32% |
| Geode Capital Management LLCas of 31 Dec 2023 | 14.62k | 0.30% |
| Tower Research Capital LLCas of 31 Dec 2023 | 10.72k | 0.22% |
| UBS Securities LLCas of 31 Dec 2023 | 10.29k | 0.21% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2023 | 10.00k | 0.20% |
| Qube Research & Technologies Ltd.as of 31 Dec 2023 | 50.00 | 0.00% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
